September 20, 2022
Preclinical results support intranasal delivery of IAVI’s COVID-19 vaccine candidate.
Features
September 1, 2022
Covering HIV, TB, and Lassa virus vaccines, from basic science and clinical trials to social and ethical issues related to vaccine development and tes...
August 29, 2022
IAVI recognizes the government of Japan’s continued commitment to HIV vaccine research and applauds their leadership in the fight against infectious...
August 17, 2022
Global health experts urge developers to plan for vaccine equity in new commentary.
July 27, 2022
Guide aims to ensure future HIV mAb products are affordable and globally accessible.
July 15, 2022
IAVI to participate in the 24th International AIDS Conference beginning July 29 in Montreal, Canada, and virtually
July 13, 2022
IAVI colleagues share their reflections on the importance of Pride for the global HIV response and global health research.
Jordan R. Willis, Ph.D., senior principal scientist, IAVI Neutralizing Antibody Center, Schief Lab, La Jolla, CA/Kansas City, MO
On this HVAD, our colleagues share perspectives on how an HIV vaccine can be developed with the people it seeks to benefit most.
This test sensitively quantifies diverse strains of HIV to advance vaccine and cure research.
Nkengasong was a founding leader of PEPFAR and served on IAVI’s board of directors.
Show More
Media Contacts
North America
Rose Catlos
+1 212 847 1049
RCatlos@iavi.org
